LIDOCAINE HYDROCHLO

The Defense Logistics Agency awarded a delivery order under base contract SPE2DX25D9900 to DMS PHARMACEUTICAL GROUP INC, identified by CAGE code 1UNB0, for the supply of one unit of LIDOCAINE HYDROCHLORIDE (NSN 6505016007766) at a total value of $254.33. The award was issued on July 20, 2026, with a required delivery date of August 4, 2026, and performance is to be completed FOB destination at Fort Bragg, North Carolina. The item must be shipped using the fastest traceable means, with parcel post expressly prohibited, and all packaging must be clearly marked with the contract number SPE2DP26F7756, NSN, and tracking number W8002S60291267 to ensure full traceability. Government inspection and acceptance occur at the delivery point, with final certification requiring the signature of an authorized government representative. Payment will be processed by the Defense Finance and Accounting Service in Columbus, Ohio, using the appropriation code BX: 97X4930 5CBX 001 2620 S33189. DMS PHARMACEUTICAL GROUP INC is certified as a small business with additional status as a Small Disadvantaged Business and a Women-Owned Small Business, triggering ongoing compliance obligations under 13 CFR Parts 124 and 127 and requiring continuous verification in SAM.gov. No specific packaging standards, preservation requirements, or MIL-STD references are stated, though the nature of the pharmaceutical product implies sensitivity to environmental conditions. The contract contains no options, quantitative variances, or special requirements beyond delivery, marking, and acceptance instructions, and no contractual clauses from FAR or DFAR are identified in the documentation. The ordering officer is LISA QUINN, with Shairy M. Cartagena listed as the administrative contact, and no Contracting Officer’s Representative is named. The procurement is consistent with low-value, non-complex DLA commodity acquisitions, likely awarded on a Lowest Price Technically Acceptable basis. All administrative data, including invoicing and payment protocols, are standardized under DLA procedures, and no formal evaluation factors, clauses, or attachments are documented in the provided materials.